How much does a box of Vorinostat cost?

Vorinostat, the first HDAC inhibitor approved for the treatment of cancer, was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or relapsing disease and receiving two systemic therapies.

The approval was based on a pivotal Phase IIb multicenter trial of vorinostat monotherapy that included 74 patients with persistent, progressive, or relapsed stage Ib or higher cutaneous T-cell lymphoma who had received at least two prior systemic therapies, including bexarotane( bexarotene), the study results showed an objective response rate of 30%. The most common drug-related adverse events were diarrhea, fatigue, nausea and anorexia. Most of these adverse events were grade 2 or lower. Combination chemotherapy or chemoradiotherapy is often preferred over monotherapy to maximize treatment efficacy but may be associated with increased toxicity. Vorinostat has a different mechanism of action; therefore, it can be used in combination with other systemic agents to improve clinical efficacy with no or minimal overlapping toxicities.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.